Name

Enodia Therapeutics

Legal name

Enodia Therapeutics

Website

https://www.enodiatx.com/

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing small-molecule therapies for targeted protein degradation. Revenue generation anticipated through eventual pharmaceutical partnerships, licensing deals, and product commercialization following successful clinical development.
2. Asset Acquisition Payments: Kezar Life Sciences receives $1 million upfront payment and up to $127 million in potential development, regulatory, and commercialization milestone payments, plus tiered royalties on net sales from the acquired Sec61 program.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Enodia Therapeutics develops small-molecule therapies that selectively modulate the SEC61 translocon to degrade disease-driving secreted and transmembrane proteins at the point of synthesis, before they can cause damage. The company combines proprietary proteomics, machine learning, signal-peptide-informed cell line libraries, and Cryo-EM structural data to rationally design selective SEC61 inhibitors. Lead programs target inflammatory and autoimmune diseases, with pipeline expansion potential into oncology and viral infections, including the recently acquired clinical-stage candidate KZR-261 from Kezar Life Sciences.

Product overview

Enodia Therapeutics is developing a unified SEC61 Translocon-Modulating Platform for targeted protein degradation at the point of synthesis. The platform integrates machine learning, proteomics-informed secretome analysis, and structural validation (Cryo-EM) to design selective small-molecule inhibitors. The company's pipeline includes lead programs for autoimmune and inflammatory diseases, with potential expansion into oncology and virology. The platform leverages an acquired clinical-stage asset (KZR-261) and extensive preclinical datasets from Kezar Life Sciences to strengthen the company's therapeutic offerings across inflammation, immunology, and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• SEC61 Translocon-Modulating Platform Proprietary discovery platform that uses machine learning, proteomics-informed secretome analysis, signal-peptide cell line libraries, and Cryo-EM structural validation to selectively modulate the SEC61 translocon, enabling targeted protein degradation at the point of synthesis before disease-causing proteins are secreted. Used internally to generate SEC61 inhibitor candidates for inflammatory, autoimmune, oncological, and viral indications.
• Lead Programs for Autoimmune and Inflammatory Diseases Two preclinical small-molecule SEC61 inhibitor drug candidates designed for inflammatory and autoimmune diseases, with potential applications extending into oncology and viral infections. Leverages the SEC61 Translocon-Modulating Platform and is being advanced toward preclinical candidate selection.
• KZR-261 Clinical-stage Sec61 inhibitor previously advanced by Kezar Life Sciences, which had initiated a Phase I trial in solid tumor patients in 2021 before terminating it. Acquired by Enodia Therapeutics to strengthen the SEC61 portfolio and accelerate development of small-molecule inhibitors.

Quantifiable outcome

• 95% of secreted proteins and 80% of transmembrane proteins can be targeted through Sec61 modulation
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Kezar Life SciencescoreStrategic or Co-development Partner · 8 January 2026Enodia acquired Kezar's Sec61-based discovery and development program assets including preclinical datasets and the clinical-stage drug candidate KZR-261. Deal includes $1 million upfront payment and up to $127 million in potential milestone payments plus tiered royalties. Kezar spent nearly ten years pioneering Sec61 translocon research, which Enodia will advance.
• Institut PasteurcoreStrategic or Co-development PartnerEnodia originated from foundational research at Institut Pasteur led by Prof. Caroline Demangel, who discovered the mechanism of action of mycolactone (a natural Sec61 inhibitor). The company was built on science from Institut Pasteur's Immunobiology and Therapy Research Unit. Institut Pasteur is also an investor and board observer.
• Argobio StudiocoreStrategic or Co-development PartnerArgobio is the startup studio that selected, incubated, and built Enodia Therapeutics. The company was created by Argobio Studio and The Institut Pasteur. Argobio provides ongoing board representation and strategic support.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses5 records

Competitive moat3 records

Customer concentration

• LinkedInlinkedin.com/company/enodiatx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enodia Therapeutics